Kornimate/medical-research-clean huggingface dataset:
efficacy of proton pump inhibitors in gastrointestinal erosions and/or ulcers

Conditions: Gastrointestinal Erosions and/or Ulcers

Summary: the aim of this study is to collect the data of clinical efficacy and safety after the usage of bonoprazon and esomeprazole when the patients take nsaids more than 2 weeks and have gastrointestinal symptoms who have had gastrointestinal erosions and/or ulcers in the past.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of nsaids-induced gastrointestinal erosions and/or ulcers who want to take bonoprazan or esomeprazole exclusion criteria: * patients allergic to bonoprazan or esomeprazole
investigation of the regulation of retinal and choroidal blood vessels in various al based on wf ss-octa detection with changes in body position

Conditions: Myopia

Summary: this prospective observational study aims to understand the effects of different subaxial body positions on choroidal and retinal blood vessel density. the main questions it aims to answer are as follows:1) how do retinal and choroidal blood vessels adjust and repair after changes in body position?2) is the change of body position related to the factors that cause myopia？ 3) are there any differences in the regulation ability of fundus blood vessels in people with different ocular axes under the condition of changes in body position?

this project will use the wide field swept-source optical coherence tomography angiography, combined with data analysis and mining methods, to explore the self-adjustment and change mode and mechanism of retinal and choroidal blood vessels in the case of posture changes in an all-round and multi-angle way. there would be three kinds of postural changes, one is 15° head-up position, one is supine position, and the other is 15° head-down position. relevant ophthalmological measurements would be performed before and after the postural changes. the objective is to discover the three-dimensional change mode of retinal and choroid blood vessels in different postures and compare the differences among people with different lengths of ocular axes, and to elucidate the relationship between the mode and ability of retinal and choroidal blood vessels to adjust and repair changes after changes in body position and myopia, to provide more ideas and objective basis for the occurrence and development of myopia, and lay a foundation for further research. it is of great significance to innovate the pathogenesis of myopia, deepen the theoretical understanding, and guide the prevention and control of myopia.

Eligibility criteria:
inclusion criteria: 1. corrected visual acuity ≥1.0 (international standard visual acuity chart); 2. age 10-40 years old; 3. in good health; 4. give informed consent and volunteer for the study. the process of obtaining informed consent complies with gcp regulations. exclusion criteria: 1. can not cooperate with the completion of relevant inspection and data collection; 2. pregnant and lactating women; 3. patients with amblyopia, glaucoma, retinitis pigmentosa, senile macular degeneration, retinal artery obstruction, retinal vein obstruction, diabetic retinopathy and other eye diseases that may affect the blood circulation and vascular diameter of the retina and vein, or those who have undergone intraocular surgery; 4. patients with cardiovascular and cerebrovascular diseases, endocrine diseases, autoimmune diseases; 5. long history of smoking and drinking; 6. history of ocular trauma; 7. the mentally ill; 8. those who have taken drugs that affect blood circulation in the past 3 months;
median effective dose of cisatracurium for the prevention of fasciculation caused by the injection of succinylcholine

Conditions: Fasciculation; Succinylcholine

Summary: succinylcholine is currently the only depolarizing neuromuscular blocker widely used in anesthesia induction and is the drug of choice for rapid sequential anesthesia induction. however, with succinylcholine, varying degrees of muscle fibrillation and muscle pain occur. intravenous injection of succinylcholine caused by myomuscular fibrillation can cause increased intragastric pressure, intraocular pressure and intracranial pressure, increased serum potassium and postoperative myalgia, increased the incidence of adverse events such as needle prolapse, extravasation of injected drugs, and reduced perioperative comfort of patients. pretreatment with cisatracurium provides limited prevention of muscular fibrillation due to succinylcholine, but the choice of dose often depends on user experience, and there have been no previous studies of age-related doses of cisatracurium for the prevention of muscular fibrillation caused by succinylcholine, and its half-effective amount (ed50) has not been established. in this study, patients treated with elective general anesthesia surgery were the subjects, and in the process of general anesthesia induction, cis-atracurium was pretreated to evaluate the degree of inhibition of muscular fibrillation caused by succinylcholine, and half of the effective dose of cis-atracurium inhibition of muscular fibrillation caused by succinylcholine was calculated by sequential method.


Eligibility criteria:
inclusion criteria: 1. ages ranged from 18 to 80. 2. asa # or # level. exclusion criteria: * allergy or contraindication to cisatracurium or succinylcholine; * associated with cardiovascular disease, diabetes, hyperkalemia, increased intraocular pressure, increased intracranial pressure, gastroesophageal reflux, difficult airway, malignant hyperthermia, neuromuscular disease sick; * take drugs that may affect neuromuscular function before surgery * liver or kidney failure * pregnancy
local inflammation in arrhythmogenic right ventricular cardiomyopathy

Conditions: Arrhythmogenic Right Ventricular Dysplasia

Summary: the understanding of arvc pathophysiology remains incomplete. several clues indicate that disease progression is mediated through inflammation. the present study aim to document the feasibility of detecting the potential presence of intracardiac local inflammatory components in patients with arvc.

arrhythmogenic right ventricular cardiomyopathy (arvc) is a heritable condition characterized by right ventricular (rv) dilatation/dysfunction and malignant ventricular arrhythmias. the understanding of arvc pathophysiology remains incomplete. several clues indicate that disease progression is mediated through inflammation. first, presence of subepicardial late gadolinium enhancement sharing the same characteristics as the ones found in myocarditis is common on cardiac magnetic resonance imaging (cmr). second, clinical pathology findings of inflammatory infiltrates of mononuclear cells are frequent and correlate to the extent and severity of arvc. finally, from a biological standpoint, the exploratory study conducted by campian et al. has shown an exaggerated humoral inflammatory response in peripheral blood whilst anti-desmoglein-2 antibodies (targeting a component of the desmosome) emerge as a sensitive and specific biomarker for arvc. as specific treatments for arvc are currently lacking, a better understanding of the humoral pathophysiology of the disease could unlock new therapeutic targets. we recently demonstrated that collecting local cardiomyocytes was feasible through irrigated ablation catheters in patients with arvc. these steerable catheters may easily map the whole right ventricle and locate endocardial or epicardial scars. aspiration of local blood or cellular material through the inner lumen of the catheter once pressed on the parietal wall may be an interesting technique for retrieving local inflammation markers.

Eligibility criteria:
inclusion criteria: * for cases: * arrhythmogenic right ventricular dysplasia diagnosed (according to 2010 task force criteria) * admitted for right ventricle electrophysiologic mapping * for controls \* admitted for ablation procedures (accessory pathway, atrial flutter) on otherwise healthy hearts. exclusion criteria: * diagnostic of systemic chronic inflammatory disease * presence of possible or proven cardiac involvement of an inflammatory disease, an acute or chronic infectious disease. * taking immunosuppressant or immunomodulating medications

Keywords: cardiac electrophysiologic techniques inflammation cytokines interleukin-1 interleukin-6 interleukin-10 transforming growth factor beta tumor necrosis factor-alpha
efficacy and safety of som3355 in huntington's disease chorea

Conditions: Huntington's Chorea

Summary: phase iia study to evaluate the efficacy and safety of som3355 in chorea movements associated with huntington's disease


Eligibility criteria:
inclusion criteria: * subject is at least 18 years of age at time of consent. * diagnosis of hd definite by a movement disorders expert and confirmed by a number of htt gene cag repeats equal or greater than 36. * female of child bearing potential (fcbp) and non-vasectomized male agree to practice appropriate methods of birth control. * ability to walk independently or with minimal assistance. * uhdrs tmc score equal or greater than 8. * uhdrs tfc equal or greater than 4. * subject has provided written informed consent or through his/her legally authorized representative. exclusion criteria: * onset of hd symptoms prior to age 18 (juvenile forms of hd). * non-ambulatory patients. * a past medical history of clinically significant ecg abnormalities or a family history (grandparents, parents and siblings) of a prolonged qt-interval syndrome. * pregnant or breastfeeding female patients, including those planning to conceive during the period of the trial. * patients with psychiatric symptoms, or other impairments, that would interfere with their full compliance with the investigator instructions and testing, unless there is an identified caregiver to support the patient. * any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of drugs, or which may jeopardize the subject in case of participation in the study. the investigator should make this determination in consideration of the subject's medical history and/or clinical laboratory test results at screening and baseline. * known allergy/sensitivity/intolerance to the study drugs or their excipients. * any significant laboratory results which, in the investigator's opinion, would not be compatible with study participation or represent a risk for the subject while in the study. * prescribed anti-hypertensive medication, tetrabenazine, deutetrabenazine or valbenazine within 15 days prior starting the investigational treatment. * excluded concomitant medications: any anti-hypertensive medication, tetrabenazine, deutetrabenazine or valbenazine, all typical neuroleptics and all mao inhibitors * subject has a history of alcohol or substance abuse in the previous 12 months. * patients with diabetic ketoacidosis or metabolic acidosis. * patients with cardiogenic shock, congestive heart failure, pulmonary hypertension due to right-sided heart failure, severe sinus bradycardia, atrioventricular block (grades ii and iii) or sinoatrial block. * subject has participated in an investigational drug or device trial within 30 days prior starting the investigational treatment.

Keywords: huntington chorea som3355
phase 1b study of ksp/qrh dimer for detection of neoplasia in the esophagus

Conditions: Barrett Esophagus

Summary: the overall aim of this feasibility study is to develop new technologies for improved detection of barrett's neoplasia using the scanning fiber endoscope (sfe) imaging system. this study will combine the use of a fluorescent-labeled peptide dimer that bind specifically to pre-cancerous mucosa in the esophagus for use as a novel imaging agent to guide endoscopic biopsy or endoscopic mucosal resection (emr). this phase 1b study will be used to provide early evidence of efficacy for the topical application of a peptide dimer that binds to molecular targets, including egfr and her2, that are specific for esophageal dysplasia. a dimer is needed because cancer in the esophagus is genetically heterogeneous. qrh binds specifically to epidermal growth factor receptor (egfr), and ksp binds specifically to human epithelial growth factor receptor (her2). the study will look at peptide binding in subjects with known or suspected barrett's esophagus.


Eligibility criteria:
inclusion criteria: * has known or suspected barrett's esophagus * scheduled for a clinically-indicated, upper endoscopy * subject is medically cleared for the procedure (e.g. washout for anticoagulants, co-morbidities) * age 18 to 100 years * willing and able to sign informed consent exclusion criteria: * subjects with known allergy or negative reaction to the near infrared fluorophore irdye800cw, or derivatives * subjects on active chemotherapy or radiation treatment * pregnant or trying to conceive
pegylated interferon lambda treatment for covid-19

Conditions: COVID-19; COVID

Summary: prospective randomized trial to assess the antiviral efficacy of pegylated interferon lambda (180 mcg sc injection) vs.placebo in up to 20 subjects with covid-19 infection.

the study objective is to assess the efficacy of pegylated interferon lambda (180 mcg) vs. placebo in inducting quantitative pcr negativity at day 7

Eligibility criteria:
inclusion criteria: * able to provide informed consent * confirmed covid-19 diagnosis based on pcr analysis of respiratory secretions * positive sars-cov-2 rt-pcr test must be within 48 hours of randomization exclusion criteria: * clinically-significant illness or any other major medical disorder that in the opinion of the investigator, may interfere with subject treatment, assessment or compliance with the protocol * treatment with ifn or other immunomodulatory/immunosuppressive agent within 12 months before screening. * respiratory compromise requiring ventilatory support other than nasal cannula (mask, bipap or intubation and mechanical ventilation) * history of treatment with any of the following medications within five half-lives or 30 days before administration of the study drug (whichever is longer): anti-il-6, anti-il6r antagonists, janus kinase inhibitors, ustekinumab (anti-il-12/23), or anti il-23 agents (guselkumab). * life threatening sae during the screening period * pregnant or nursing females * platelet count \<90,000 cells/mm3 * wbc count \<3,000 cells/mm3 * anc \<1,500 cells/mm3 * hb \<11 g/dl for women and \<12 g/dl for men * crcl \< 50 ml/min * bilirubin level ≥ 1.5x uln * inr ≥1.5 (except in the setting of concomitant anticoagulant use) * crp \> 200 mg/l * clinically-relevant alcohol or drug abuse within 12 months of screening * known hypersensitivity to interferons * current or planned participation in an investigational new drug (ind) trial from 30-days prior to randomization through day 14 post treatment

Keywords: covid coronavirus
open-label treatment with mpc-7869 for patients with alzheimer's who previously participated in an mpc-7869 protocol

Conditions: Alzheimer's Disease

Summary: open-label treatment with mpc-7869 for participants in a previous randomized study.


Eligibility criteria:
inclusion criteria: * participation in a previous mpc-7869 randomized protocol * have had a diagnosis of probable alzheimer's disease. * men or women ages 55 years or greater and living in the community at the time of enrollment (i.e., not living in a rest home or nursing care facility). * signed the subject informed consent form and is willing and able to participate for the duration of the study. * female subjects must be surgically sterile or postmenopausal for \> 1 year. * subjects must have a reliable caregiver who can read, understand and speak english or spanish. exclusion criteria: * history or evidence of, active malignancy, except for basal cell carcinoma or squamous cell carcinoma of the skin, within the 24 months prior to entry. men with prostate cancer may be enrolled at the discretion of the sponsor. * chronic or acute renal, hepatic or metabolic disorder. * use of any investigational therapy within 30 days, or 5 half-lives, whichever is longer, and/or use of ad immunotherapy prior to screening.

Keywords: alzheimer's dementia dementia of alzheimer type
estrogen replacement therapy in treating women with early-stage endometrial cancer

Conditions: Endometrial Cancer

Summary: rationale: estrogen replacement therapy may improve quality-of-life in postmenopausal women with endometrial cancer. it is not yet known whether estrogen replacement therapy will affect cancer recurrence. purpose: randomized double-blinded phase iii trial to determine the effectiveness of estrogen replacement therapy in treating women who have stage i or stage ii endometrial cancer.

objectives: * determine the effect of estrogen replacement therapy on recurrence free and overall survival in women with a history of stage i or ii endometrial adenocarcinoma. outline: this is a randomized, double blind study. patients are stratified according to stage of endometrial cancer (ia vs ib/ic vs ii). patients are randomized to one of two treatment arms: * arm i: patients receive oral conjugated estrogens (premarin) daily for 3 years. * arm ii: patients receive oral placebo daily for 3 years. patients are followed every 6 months for 3 years and then annually for 2 years. projected accrual: approximately 2,108 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * histologically confirmed grade i, ii or iii endometrial adenocarcinoma (endometrioid, villoglandular, mucinous, adenosquamous, papillary serous, clear cell, or not otherwise specified) * must have had total hysterectomy and bilateral salpingo-oophorectomy within past 20 weeks * surgical stage ia, ib, ic, iia (occult), or iib (occult) disease * must have had normal mammogram, or a negative breast biopsy after an abnormal mammogram, within past year patient characteristics: age: * not specified performance status: * not specified life expectancy: * not specified hematopoietic: * not specified hepatic: * bilirubin no greater than 1.5 times normal * sgot no greater than 3 times normal * no acute liver disease renal: * not specified cardiovascular: * no prior thromboembolic disease other: * no prior or current carcinoma of the breast * no other prior invasive malignancy within the past 5 years except nonmelanoma skin cancer prior concurrent therapy: biologic therapy: * not specified chemotherapy: * not specified endocrine therapy: * no concurrent hormonal therapy radiotherapy: * not specified surgery: * see disease characteristics * recovered from prior surgery other: * no prior cancer treatment that would preclude study therapy * concurrent participation on gog lap-1 or gog lap-2 allowed

Keywords: stage i endometrial carcinoma stage ii endometrial carcinoma endometrial adenocarcinoma
restoring sleep homeostasis to lower blood pressure

Conditions: Hypertension; Pre-hypertension

Summary: cutting back on sleep duration has developed into a common, highly prevalent habit in the adult population, and may lead to a major health problem. large epidemiological studies have demonstrated that short sleep duration is associated with increased risk of cardiovascular disease (cvd). the investigators' preliminary data on the effects of experimental sleep reduction have shown elevation of blood pressure (bp) and inflammatory markers, such as interleukin-6 (il-6) and c reactive protein (crp), suggesting that both may play an important role in linking sleep loss and cvd risk. with this background, the investigators hypothesize that restoring sleep homeostasis, i. e. getting adequate amounts of sleep, is an effective behavioral intervention in the treatment of elevated bp. the investigators will test this hypothesis in subjects with bp above normal and with short habitual sleep duration, as verified by sleep logs and actigraphic recordings. subjects will either undergo 6 weeks of mild sleep extension, in which 60 min of bedtime will be added to the habitual sleep duration, or subjects will maintain their habitual sleep duration for the following 6 weeks. regarding their first specific aim, the investigators expect that sleep extension across 6 weeks will lower bp, inflammatory (il-6, crp, cell adhesion molecules) and autonomic markers (catecholamines). in particular, the investigators expect that in subjects with mild bp elevation, i. e. with pre-hypertension, sleep extension leads to normalization of bp. this study presents a very first approach in using sleep behavior components for the treatment of elevated bp. therefore, the investigators' second specific aim will characterize the strength of associations between changes in sleep duration, bp, and inflammation, and they will explore factors that are predictive for these changes. in particular, adiposity, as measured by percent body fat, has frequently been shown to be related to short sleep duration and inflammatory processes, but the role of adiposity in modulating the physiological consequences of changes in sleep duration has never been addressed. if the investigators' hypothesis is correct, sleep extension may be considered as an additional component in current lifestyle intervention programs in combating and preventing hypertension.


Eligibility criteria:
inclusion criteria: * current history of prehypertension or stage 1 hypertension * sleep duration \<= 7 hours/night exclusion criteria: * sleep disorders * history of psychiatric or severe medical disorders * regular medication intake, except anti-hypertensive and birth control medication

Keywords: hypertension sleep blood pressure inflammatory markers
histological improvement of nash with prebiotic

Conditions: Non-Alcoholic Fatty Liver Disease

Summary: this trial will investigate the therapeutic potential of a prebiotic supplement to improve histological parameters of nash. in a single-blind, placebo controlled, randomized pilot trial will be conduced in individuals with liver biopsy confirmed nash (non-alcoholic fatty liver activity score (nas) ≥ 5). participants will be randomized to receive oligofructose (8 g/day for 12 weeks and 16g/day for 24 weeks) or isocaloric placebo for 9 months. the primary outcome measure is the change in liver biopsy nas score and the secondary outcomes include changes in body weight, body composition, glucose tolerance, serum lipids, inflammatory markers, and gut microbiota.

oligofructose and maltodextrin are both white powders that taste and look the same. they were both package in individual foil packets. participants were blinded to the treatment allocation. adherence to supplement protocol was monitored throughout the study through direct questioning and counting unused supplement packages. participants were asked to maintain their usual physical activity.

Eligibility criteria:
inclusion criteria: * liver biopsy confirmed nash (nas score greater than or equal to 5) * bmi \>25 kg/m2 (caucasians) * \>23 kg/m2 (asians) * history of serum alt \>1.5x upper normal limit * no changes in lipid-lowering or diabetes medication over previous three months * ability to provide informed consent exclusion criteria: * alcohol consumption \>20g/day (women) or \>30g/day (men) * alternate etiology for abnormal liver enzymes * decompensated liver disease * use of orlistat, liraglutide, prebiotic, probiotic, or antibiotic within 3 months prior to enrollment

Keywords: gut microbiota prebiotic liver biopsy oligofructose